Open Access
Volume 9, Number 3, September 2019
Article Number 16
Number of page(s) 6
Published online 27 August 2019
  1. Hermansen M-LF, Hummelshø L, Lundsgaard D, Hornum L, Keller P. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosuspatients. Lupus. 2012; 21: 1098–104. [CrossRef] [PubMed] [Google Scholar]
  2. Kim H, Jeon J, Jeong-Moon Y. Beta2-Microglobulin Can Be a Disease Activity Marker in Systemic Lupus Erythematosus. AJMS. 2010; 339(4): 337–40. [CrossRef] [Google Scholar]
  3. Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity. 2006; 39: 705–9. [CrossRef] [PubMed] [Google Scholar]
  4. Badr Abeer M, El-Melligy Dalal Mohamed, Mostafa Heba, El Deeb Somaya. 1 Evaluation of Beta2-Microglobulin as a Possible Biomarker for Assessment of Disease Activity in Systemic Lupus Erythematosus and Chronic Kidney Disease. World J Med Sci. 2005; 12(1): 26–35. [Google Scholar]
  5. Kanne JP, Yandow DR, Haemel AK, Meyer CA. Beyond Skin deep: thoracic manifestations of systemic disorders affecting the skin. Radiographics. 2011; 31: 1651–68. [CrossRef] [PubMed] [Google Scholar]
  6. Midgly A. Systemic Lupus Erythematosus (SLE). Category: Immune Dysfunction. British Society for Immunology. Bitsized Immunology. 2018. [Google Scholar]
  7. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985; 64(5): 285–95. [CrossRef] [PubMed] [Google Scholar]
  8. Davies K, Bukhari M, Ottewell L. Acroosteolysis in a patient with systemic lupus erythematosus/mixed connective tissue disease. Rheumatology (Oxford). 2018; 12: 1–8. [Google Scholar]
  9. Mira-Avendano IC, Abril A. Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease. Rheum Dis Clin North Am. 2015; 41(2): 263–77. [CrossRef] [PubMed] [Google Scholar]
  10. Williams JN, Chang SC, Sinnette C, Malspeis S, Parks CG, Karlson EW, et al. Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women. Lupus. 2018; 27(13): 2129–34. [CrossRef] [PubMed] [Google Scholar]
  11. Ho Ch. Lupus Erythematosus, Drug-Induced. StatPearls Internet. Treasure Island (FL): StatPearls. 2018; 1–8. [Google Scholar]
  12. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301(1): 99–105. [CrossRef] [PubMed] [Google Scholar]
  13. Chlebus E, Wolska H, Blaszczyk M, Jablonska S. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol. 1998; 38(3): 405–12. [CrossRef] [PubMed] [Google Scholar]
  14. Tony E, Mohammed H, Fathi N, Tonys Abeer A, Afifi Ola, Abdou Madleen Adel A, Gamal Rania M. Serum and Urinary Biomarkers, Endothelin-1, Beta-2 Microglobulin, Cystatin C, Galectin-3 and Alpha-1-acid Glycoprotein; Can they Surrogate Clinical and Histological Staging in Lupus Nephritis Patients?. J Arthritis. 2016; 5: 6–9. [Google Scholar]
  15. Choi J. The Pathogenesis of Systemic Lupus Erythematosus – An Update. Curr Opin Immunol. 2012; 24(6): 651–7. [CrossRef] [PubMed] [Google Scholar]
  16. Delgado-Vega. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol. 2010; 22: 698–705. [CrossRef] [PubMed] [Google Scholar]
  17. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010; 6: 683–92. [CrossRef] [PubMed] [Google Scholar]
  18. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011; 7: e1001311. [CrossRef] [PubMed] [Google Scholar]
  19. Skare T. Systemic lupus erythematosus activity and beta two microglobulin levels. Sao Paulo Med J. 2014; 132(4): 239–42. [CrossRef] [PubMed] [Google Scholar]
  20. Gladman DD, Ibenz D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002; 29: 288–91. [PubMed] [Google Scholar]
  21. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment lupus flares measured by the BILAG index. Rheumatology. 2003; 42: 1372–9. [CrossRef] [PubMed] [Google Scholar]
  22. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Semin Immunopathol. 2005; 27: 276–85. [Google Scholar]
  23. Żychowska I, Suszek D, Dryglewska M, Majdan M. β2-micro- globulin as a marker of systemic lupus erythematosus activity. Adv Clin Exp Med. 2018; 27(3): 379–82. [CrossRef] [PubMed] [Google Scholar]
  24. Wibell LB. Studies on beta2-microglobulin in patients and normal subjects. Acta Clin Belg. 1976; 31: 14–26. [Google Scholar]
  25. Choe Y. Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus. SAGE J. 2014; 8: 1–10. [Google Scholar]
  26. Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity. 2010; 33: 967–78. [CrossRef] [PubMed] [Google Scholar]
  27. Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol. 2012; 1–9. [Google Scholar]
  28. Craft JE. Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med. 2011; 3: 73–9. [Google Scholar]
  29. Evrin PE, Strom T. Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis. 1984; 43: 267–74. [CrossRef] [PubMed] [Google Scholar]
  30. Latt D, Weiss JB, Jayson MI. Beta 2-microglobulin levels in serum and urine of rheumatoid arthritis patients on gold therapy. Ann Rheum Dis. 1981; 40: 157–60. [CrossRef] [PubMed] [Google Scholar]
  31. Strom T, Evrin PE, Karlsson A. Serum beta-2-microglobulin in Sjogren’s syndrome. Scand J Rheumatol. 1978; 7: 97–100. [CrossRef] [PubMed] [Google Scholar]
  32. Yeung CK, Wong KL, Wong WS, Chan KH. beta 2-Microglobulin and systemic lupus erythematosus. J Rheumatol. 1986; 13(6): 1053–8. [PubMed] [Google Scholar]
  33. Żychowska Iwona. β2-microglobulin as a marker of systemic lupus erythematosus activity. Advances in Clinical and Experimental Medicine. Adv Clin Exp Med. 2018; 27(3): 379–82. [CrossRef] [PubMed] [Google Scholar]
  34. Hermansen ML, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, et al. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus. 2012; 21(10): 1098–104. [CrossRef] [PubMed] [Google Scholar]
  35. Font J. Serum beta 2-microglobulin as a marker of activity in systemic lupus erythematosus. Scand J Rheumatol. 1986; 15(2): 201–5. [CrossRef] [PubMed] [Google Scholar]
  36. Maury CP, Helve T, Sjoblom C. Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int. 1982; 2: 145–9. [CrossRef] [PubMed] [Google Scholar]
  37. Curry R, Thoen J, Shelborne C, Gaudernack G, Messner R. Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients. Arthritis Rheum. 1982; 25: 375–80. [CrossRef] [PubMed] [Google Scholar]
  38. Karlsson FA, Wibell L, Evrin PE. Beta 2-microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl. 1980; 154: 27–37. [PubMed] [Google Scholar]
  39. Wakabayashi K, Inokuma S, Matsubara E, Onishi K, Asashima H, Nakachi S, et al. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adultonset Still’s disease. Clin Rheumatol. 2013; 32: 999–1005. [Google Scholar]
  40. Rezaeiyazddi Z. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? SAGE Journal. 2011; 3: 1–5. [Google Scholar]
  41. Enocsson H, Sjöwall C, Kastbom A, Skogh T, Eloranta ML, Rönnblom L, et al. Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-a and a C-reactive protein gene variant. Arthritis Rheumatol. 2014; 66(6): 1568–73. [CrossRef] [PubMed] [Google Scholar]